StockDuty ← Dashboard Oct 26, 2026 01:04 AM ET
SignalFDA/Bio

Roche lung cancer drug extends survival by nearly six months in late-stage trial

Late-stage trial shows Roche lung cancer drug extends survival by nearly six months.

Late-stage trial shows Roche lung cancer drug extends survival by nearly six months.
Late-stage trial shows Roche lung cancer drug extends survival by nearly six months. — impact context not separately stored; see What changed.
Sources